Cerenome

$CNSY has completed enrollment in the Phase 2 ReSPECT-GBM study. Previously reported interim Phase 2 data showed a 63% improvement in median overall survival versus standard of care in recurrent GBM. Topline data is expected in mid-2027. Read more here: bit.ly/4By3uja

“We were previously blind, but now we see.” For clinicians and patients, navigating leptomeningeal metastases (LM) diagnosis has historically been one of oncology’s steepest hurdles. Symptoms can masquerade as almost anything from persistent headaches and gait disturbances to double vision or auditory sensations. When relying solely on subjective history and qualitative imaging LM patients face the risk of their disease going undetected or misdiagnosed. In our debut video of the CNS Cancer Clinical Perspectives series, Dr. Peter Forsyth shares insights into the qualitative limitations of standard imaging and clinical suspicion, biological complexity of the CSF compartment, and urgent necessity of precise molecular testing to inform clinical trials and targeted therapies. As we look ahead to @NeuroOnc's #SNO2026 Annual Meeting next month, $CNSY is proud to champion these vital conversations alongside the launch of our next-generation CNSide® NGS capabilities. Watch Dr. Forsyth’s perspective in the video below or on YouTube: bit.ly/4zZfXuJ Follow $CNSY and @CNSideDx for upcoming episodes in the CNS Cancer Clinical Perspectives series.

$CNSY announced that a poster presentation of interim data from its ongoing ReSPECT-LMM multidose study of REYOBIQ™ will be presented at @NeuroOnc's 31st Annual Meeting and Education Day, taking place November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia. The poster will report interim safety, dosimetry, CSF tumor cell enumeration, and individual treatment course data on the first ten patients from the multidose ReSPECT-LMM study. Cerenome will also host a sponsored symposium at #SNO2026, featuring: Dr. Michael Youssef, Dr. Andrew Brenner, and Dr. Priya Kumthekar. Learn more about the upcoming poster presentation and symposium here: bit.ly/4eXKxN9 RSVP for the symposium: bit.ly/4sp542C @CNSideDx

$CNSY announces that new preclinical data presented at the 16th Biennial Rivkin Ovarian Cancer Research Symposium illustrate the emerging immunomodulatory properties of REYOBIQ™, its lead investigational targeted radiotherapeutic. Read more: bit.ly/4i9UwQp @ocrahope

$CNSY combines @CNSideDx's detection, monitoring, molecular profiling, and biomarker characterization, REYOBIQ’s ReSPECT™ clinical trials for recurrent GBM, LM, pediatric ependymoma, and high-grade glioma, and our advanced AI clinical capabilities into one powerful platform.

CNS cancers demand more than isolated innovations. They require a connected approach that improves how disease is detected, treated, and understood over time. $CNSY's integrated platform that unites precision diagnostics, targeted therapeutics, and clinical data into one system.

$CNSY’s new CNSide® CSF Molecular Profile tests are officially available to U.S. clinicians! @CNSideDx's Tumor Cell Enumeration (TCE) test gives clinicians a reliable way to detect and track tumor cells in the CSF, and now the expanded platform with CNSide® CSF Molecular Profile tests marks an evolution from detection to deep molecular actionability. CNSide now expands beyond cell enumeration to complementary, comprehensive DNA and RNA profiling from cerebrospinal fluid, covering primary CNS tumors, brain metastases, and hematologic cancers. This marks a major step forward in delivering liquid biopsy precision to patients facing severe CNS malignancies. Hear President and General Manager of CNSide, Russell Bradley, speak further to our effective approach and technology in the video below and read the full launch announcement here: bit.ly/3VTV6Kx

$CNSY has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida (@FLBlue), effective October 1, 2026. This expands @CNSideDx's tests to contracted payer access for approximately 164 million covered lives. 🔗 bit.ly/4jL20f1

$CNSY announces the commercial launch of two new CSF-based molecular profiling tests, available to US health care professionals starting October 12. The new DNA & RNA tests expand @CNSideDx beyond LM to molecular profiling across CNS oncology. 🔗 bit.ly/3VTV6Kx @GenomicTesting

Dr. Marc Hedrick, President and CEO, and Russell Bradley, President and GM of @CNSideDx, recently joined The BioHub Podcast to discuss how $CNSY is tackling the challenges of CNS oncology research head-on. Listen/watch the full discussion here: youtube.com/watch?v=X6dRgafT…

Today we’re sharing $CNSY’s latest corporate deck, which further outlines our transition to becoming an integrated central nervous system (CNS) oncology company. Check out the full corporate deck here: bit.ly/4hBQuA6

$CNSY provides a Q3 2026 business update for its wholly owned subsidiary, @CNSideDx, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test and the expansion of the CNSide testing menu. Read more here: bit.ly/4deBEy9

CEO & President, Dr. Marc Hedrick, had a great visit to the @NYSE last month for his conversation with @FINTECHTVglobal about $CNSY's broader corporate vision. Check out their full interview: bit.ly/4gfbMUH @Nasdaq @cnsidedx

$CNSY announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to give a business update on @CNSideDx, the Company’s cerebrospinal fluid diagnostic platform. Read the full release: bit.ly/4d0p0mi